Results 11 to 20 of about 77,260 (225)

Erythema Migrans: Course and Outcome in Patients Treated With Rituximab. [PDF]

Open Forum Infect Dis, 2019
Background Information on Lyme borreliosis (LB) in patients treated with rituximab is limited to individual case reports. Methods We reviewed data on adult patients diagnosed with typical erythema migrans (EM) at the LB outpatient clinic of the ...
Maraspin V, Bogovič P, Rojko T, Ružić-Sabljić E, Strle F.   +4 more
europepmc   +4 more sources

Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice

Scandinavian Journal of Primary Health Care, 2017
Objective: Promptly treated erythema migrans (EM) has good prognosis. However, some patients report persistent symptoms. Do patients with EM have more symptoms than the general population?
Knut Eirik Eliassen, Reidar Hjetland, Harald Reiso, Morten Lindbæk, Hedda Tschudi-Madsen   +4 more
doaj   +2 more sources

No molecular detection of tick-borne pathogens in the blood of patients with erythema migrans in Belgium. [PDF]

Parasit Vectors, 2022
Background A number of tick-borne pathogens circulate in the Belgian tick population in addition to the causative agent of Lyme borreliosis. However, so far, only a few patients with tick-borne diseases other than Lyme borreliosis have been reported in ...
Geebelen L, Lernout T, Tersago K, Terryn S, Hovius JW, Docters van Leeuwen A, Van Gucht S, Speybroeck N, Sprong H.   +8 more
europepmc   +2 more sources

Single-cell immunophenotyping of the skin lesion erythema migrans identifies IgM memory B cells. [PDF]

JCI Insight, 2021
The skin lesion erythema migrans (EM) is an initial sign of the Ixodes tick–transmitted Borreliella spirochetal infection known as Lyme disease. T cells and innate immune cells have previously been shown to predominate the EM lesion and promote the ...
Jiang R, Meng H, Raddassi K, Fleming I, Hoehn KB, Dardick KR, Belperron AA, Montgomery RR, Shalek AK, Hafler DA, Kleinstein SH, Bockenstedt LK.   +11 more
europepmc   +2 more sources

Course and Outcome of Erythema Migrans in Pregnant Women. [PDF]

J Clin Med, 2020
Information on Lyme borreliosis (LB) during pregnancy is limited. In the present study, the course and outcome of erythema migrans (EM) in 304 pregnant women, diagnosed in the period 1990–2015, was assessed and compared with that in age-matched non ...
Maraspin V, Lusa L, Blejec T, Ružić-Sabljić E, Pohar Perme M, Strle F.   +5 more
europepmc   +2 more sources

Patients with Erythema Migrans: Characterizing the Impact of Initiation of Antibiotic Therapy Prior to Study Enrollment. [PDF]

Antimicrob Agents Chemother, 2020
Wormser GP, McKenna D, Jacobson E, Shanker EM, Shaffer KD, Scavarda C, Visintainer P.   +6 more
europepmc   +3 more sources

Alpha-Gal Sensitization Dynamics in Individuals After Tick Bites With or Without Erythema Migrans. [PDF]

Clin Exp Allergy
ABSTRACT α‐Gal syndrome (AGS) is an emerging tick‐borne disease characterised by the development of specific immunoglobulin E (sIgE) antibodies against galactose‐α‐1,3‐galactose (α‐gal), a carbohydrate found in most mammalian species, but not in humans. AGS occurs in individuals with a history of tick bites.
van Gorkom T, Heron M, Hofhuis A, Jongerius C, van der Klis FRM, Oude Elberink HNG, Sprong H, Thijsen SFT, Kremer K.   +8 more
europepmc   +2 more sources

Lyme disease with erythema migrans presenting concurrently with optic nerve perineuritis and abducens nerve palsy. [PDF]

BMJ Case Rep, 2020
Lundin MS, Sandel SL, Suciu CM, Spicehandler DA.   +3 more
europepmc   +2 more sources

Prospective Evaluation of the Frequency and Severity of Symptoms in Lyme Disease Patients With Erythema Migrans Compared With Matched Controls at Baseline, 6 Months, and 12 Months. [PDF]

Clin Infect Dis, 2020
BACKGROUND Erythema migrans is the most common clinical manifestation of Lyme disease. Despite antibiotic therapy, typically at least 10% of adult patients with erythema migrans experience persistence of at least 1 subjective symptom for ≥6 months ...
Wormser GP, McKenna D, Karmen CL, Shaffer KD, Silverman JH, Nowakowski J, Scavarda C, Shapiro ED, Visintainer P.   +8 more
europepmc   +2 more sources

Investigation of erythema migrans patients identifies Borrelia species and Neoehrlichia mikurensis with implications for clinical assessment. [PDF]

Sci Rep
Cronhjort S, Wilhelmsson P, Tjernberg I, Waldeck M, Henningsson AJ, Anderson C, Forsberg P, Lindgren PE.   +7 more
europepmc   +2 more sources